{"id":251812,"date":"2024-07-24T00:00:00","date_gmt":"2024-07-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcg0168-biopharma-progressive-supranuclear-palsy-epidemiology\/"},"modified":"2026-04-14T10:14:47","modified_gmt":"2026-04-14T10:14:47","slug":"epidcg0168-biopharma-progressive-supranuclear-palsy-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0168-biopharma-progressive-supranuclear-palsy-epidemiology-mature-markets\/","title":{"rendered":"Progressive Supranuclear Palsy &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of progressive supranuclear palsy (<abbr data-abbreviation-entity=\"7078\" title=\"progressive supranuclear palsy\">PSP<\/abbr>) comprises epidemiological estimates of diagnosed prevalence in the major mature pharmaceutical markets of the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan. We report the prevalence of <span class=\"abbreviation-guard\"><abbr data-abbreviation-entity=\"7078\" title=\"progressive supranuclear palsy\">PSP<\/abbr><\/span> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr data-abbreviation-entity=\"7078\" title=\"progressive supranuclear palsy\">PSP<\/abbr> forecast will answer the following question:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr data-abbreviation-entity=\"7078\" title=\"progressive supranuclear palsy\">PSP<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS<\/span> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts the following <abbr data-abbreviation-entity=\"7078\" title=\"progressive supranuclear palsy\">PSP<\/abbr> patient population:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251812","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-neurology","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251812\/revisions"}],"predecessor-version":[{"id":363770,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251812\/revisions\/363770"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}